Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled…
T Berg, K Simon, S Mauss, E Schott, R Heyne, D Klass, C Eisenbach, T Welzel, R Zachoval, G Felten, J Schulze-zur-Wiesch, M Cornberg, E Martins, L Gallo, T Warger, J Petersen · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and Aims: Long-term effective NUC therapy may lead to partial restoration of HBV-specific T cell functions. Stopping therapy in HBV-DNA suppressed HBeAg-negative patients may lead to initial viral rebound and hepatic flare followed by HBsAg clearance. We investigated HBsAg kinetics after controlled stopping of long-term TDF therapy. Methods: Subjects on effective TDF therapy for at least 4 years were randomized to either stop or to continue TDF for 144 weeks (advanced fibrosis/cirrhosis excluded). Primary endpoint is HBsAg loss at W144. TDF could be restarted in case of clinically significant hepatiti…
